Hye Yeong Nam
Overview
Explore the profile of Hye Yeong Nam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ullah I, Chung K, Bae S, Li Y, Kim C, Choi B, et al.
Mol Pharm
. 2020 Jan;
17(4):1193-1204.
PMID: 31944768
Glioblastoma multiforme (GBM) is an aggressive tumor with no curative treatment. The tumor recurrence after resection often requires chemotherapy or radiation to delay the infiltration of tumor remnants. Intracerebral chemotherapies...
2.
Beloor J, Nam H, Lee S, Kumar P
Methods Mol Biol
. 2014 Jul;
1176:115-26.
PMID: 25030923
Effective delivery of DNA or siRNA into primary cells demands an efficient delivery system. However, the significant differences in physical and molecular characteristics of the two molecules generally necessitate distinct...
3.
Florinas S, Nam H, Kim S
Mol Pharm
. 2013 Mar;
10(5):2021-30.
PMID: 23527953
RNAi-based gene therapy for cancer treatment has not shown significant clinical impact due to poor siRNA delivery to the target site. Here, we design a nonviral siRNA gene carrier using...
4.
Kim D, Hong J, Moon H, Nam H, Mok H, Jeong J, et al.
J Control Release
. 2013 Mar;
168(2):125-34.
PMID: 23500061
The cardiomyocyte apoptosis plays a critical role in the development of myocardial injury after ischemia and reperfusion. Thus, alteration of the major apoptosis-regulatory factors during myocardial ischemia-reperfusion is expected to...
5.
Nam K, Nam H, Kim P, Kim S
Biomaterials
. 2012 Aug;
33(32):8122-30.
PMID: 22871423
We developed a paclitaxel-conjugated polymeric micelle, ABP-PEG3.5k-Paclitaxel (APP) consisting of poly (ethylene glycol) (PEG) and arginine-grafted poly (cystaminebisacrylamide-diaminohexane) (ABP) for the co-delivery of gene and drug. The APP polymer self-assembled...
6.
Nam H, Nam K, Lee M, Kim S, Bull D
J Control Release
. 2012 May;
160(3):592-600.
PMID: 22546681
Arginine-grafted bio-reducible poly(disulfide amine) (ABP) was incorporated into the poly(amido amine) (PAMAM) dendrimer, creating a high molecular weight bio-reducible polymer, PAM-ABP, to overcome the limitations of the low molecular weight...
7.
Lee Y, Nam H, Kim J, Lee M, Yockman J, Shin S, et al.
Mol Ther
. 2012 Apr;
20(7):1360-6.
PMID: 22472948
Erythropoiesis-stimulating agents are widely used to treat anemia for chronic kidney disease (CKD) and cancer, however, several clinical limitations impede their effectiveness. Nonviral gene therapy systems are a novel solution...
8.
Nam H, Kim J, Kim S, Bull D
Mol Pharm
. 2012 Mar;
9(5):1302-9.
PMID: 22452378
To deliver siRNA specifically to cardiomyocytes with a high transfection efficiency, primary cardiomyocyte-targeting (PCM) and/or cell-penetrating (Tat) peptides were incorporated into the siRNA. With the addition of plasmid DNA, these...
9.
Baek I, Bai C, Hwang J, Nam H, Park J, Kim D
J Vasc Surg
. 2012 Jan;
55(3):806-814.e1.
PMID: 22226184
Objectives: Paclitaxel coating of hemodialysis grafts is effective in suppressing neointimal hyperplasia in the graft and vascular anastomosis sites. However, paclitaxel can have unwanted effects on the surrounding tissues. To...
10.
Kim J, Kim P, Nam H, Lee J, Yun C, Kim S
J Control Release
. 2011 Dec;
158(3):451-60.
PMID: 22207073
As an effort to overcome limits of adenovirus (Ad) as a systemic delivery vector for cancer therapy, we developed a novel system using oncolytic Ad plasmid DNA with two bioreducible...